Outsourcing in Clinical Trials Europe 2015May 19-20, 2015, Dusseldorf, Germany
This year sees the global Outsourcing in Clinical Trials series in Europe for the 6th year! Last year’s conference achieved record results, outselling in exhibition booth space 3 months ahead of the event, and with hundreds of industry leaders attending over the two days.
This year’s agenda is our most exciting yet, with cutting edge content to keep you at the forefront of developments in this sector. We have expanded the agenda to include more topics beyond the core Outsourcing issues, ranging from Operations, Finance issues, patient perspectives and Communications strategies. We are also including talks specifically tailored to different size companies so you can find content that is relevant to your company objectives and current projects.
We look forward to welcoming you to Düsseldorf in May!
Telephone: +44 207 936 6603
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within pharmaceutical, biotechnology, and virtual companies across Europe:CEOCMOCSOCFO
US-based specialty biopharmaceutical firm Biodel has started a Phase IIb clinical trial of its concentrated, proprietary and recombinant human insulin (RHI) based ultra-rapid-acting prandial/basal combination insulin candidate, BIOD-531.
Swiss drugmaker Novartis has presented positive results from two pivotal Phase III clinical trial programmes for QVA149 (indacaterol/glycopyrronium bromide) and NVA237 (glycopyrronium bromide) in patients with moderate-to-severe chronic obstructive p…
Clinical-stage biotechnology firm GlycoMimetics has commenced a Phase I/II clinical trial, which has been designed to assess the safety, pharmacokinetics (PK) and efficacy of the new E-selectin antagonist, GMI-1271, for acute myeloid leukaemia (AML).
Theravance Biopharma has presented the positive data from a Phase II trial of velusetrag (TD-5108), an investigational drug being developed to treat patients with gastroparesis and other gastrointestinal motility disorders.
RNAi therapeutics firm Alnylam Pharmaceuticals is seeking approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to start a Phase I/II clinical trial with ALN-AAT.
US-based clinical-stage pharmaceutical firm Adynxx has completed enrolment in a Phase II dose-ranging clinical study of its lead product candidate, AYX1, to prevent post-surgical pain.